Nova Eye Medical (Nova Eye Medical) Net Income (Continuing Operations) : $-9.60 Mil (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Nova Eye Medical Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Nova Eye Medical's Net Income (Continuing Operations) for the six months ended in Dec. 2023 was $-3.77 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.60 Mil.

Nova Eye Medical Net Income (Continuing Operations) Historical Data

The historical data trend for Nova Eye Medical's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Eye Medical Net Income (Continuing Operations) Chart

Nova Eye Medical Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-4.01

-7.13

-3.33

-5.27

-10.26

Nova Eye Medical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Income (Continuing Operations)	Get a 7-Day Free Trial															-2.20	-3.11	-4.46	-5.83	-3.77

Nova Eye Medical Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-9.60 Mil.

Nova Eye Medical (OTCPK:ELXMF) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Nova Eye Medical Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Nova Eye Medical's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Nova Eye Medical (Nova Eye Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nova Eye Medical Ltd (OTCPK:ELXMF) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

EYE:Australia

Address

107 Rundle Street, Kent Town, Adelaide, SA, AUS, 5067

Website

https://www.nova-eye.com

Nova Eye Medical Ltd is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The company's operating segment include AlphaRET and Glaucoma Surgical Devices, it generates maximum revenue from Glaucoma Surgical Devices. Geographically, it derives a majority of revenue from the United States of America.

Nova Eye Medical (Nova Eye Medical) Headlines

From GuruFocus

Nova Eye Medical Announces U.S. Market Clearance of the iTrack� Advance Canaloplasty Device

By Business Wire Business Wire • 04-12-2023

ABK Biomedical Appoints Michael J. Mangano as President and Chief Executive Officer

By PRNewswire PRNewswire • 07-30-2018